GlassScriptPhysician profile
Jeri Bell
NPI 1801498886
$2,967.11
in general payments reported to CMS, 2019-2025
26 companies · $757 in 2025
The $757 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $529 · 2023: $502 · 2024: $807 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $971.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $335.54 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $306.23 | 2021-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $203.99 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $141.00 | 2023-2025 | |
| Dexcom, INC. | $139.73 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.07 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $89.60 | 2021-2024 | Zepbound, Jardiance |
| Boston Scientific Corporation | $88.29 | 2022-2025 | Watchman Flx |
| Xeris Pharmaceuticals, INC. | $77.07 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $72.84 | 2021-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $59.55 | 2022 | |
| Glaxosmithkline, LLC. | $58.03 | 2021-2025 | Trelegy Ellipta |
| Ardelyx, INC. | $44.16 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.12 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.71 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $28.64 | 2022-2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $28.41 | 2021 | |
| Amarin Pharma, INC. | $27.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.62 | 2022 | |
| Astellas Pharma US INC | $25.76 | 2021 | |
| Sonex Health, INC. | $19.02 | 2025 | Sx-One Microknife |
| Biohaven Pharmaceuticals, INC. | $17.33 | 2021 | |
| Merck Sharp & Dohme LLC | $12.79 | 2023 | Rotateq, Vaxelis, Vaxneuvance |
| Nestle Healthcare Nutrition INC. | $11.55 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.47 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeri Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.